

# DocMode Health Technologies Limited

(Previously known as Docmode Health Technologies Private Limited)

**Reg Office** : 307, Shivai Plaza,  
Marol Cooperative Industrial Estate  
Road, Sagbag, Marol, Andheri East,  
Mumbai - 400059, Maharashtra.

**CIN** : U74999MH2017PLC297413

**Contact no** : +91 90821 70046

**Email** : support@docmode.org

**Website** : www.docmode.org



[www.docmode.org](http://www.docmode.org)

Transforming Learning and Practice

**Date:** 19.11.2024

To,  
The Manager / Secretary – Listing,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: **DHTL**

**Subject: Delay in submission of financial results for the half year ended 30<sup>th</sup> September, 2024**

Dear Sir / Madam,

Pursuant to the outcome of Board Meeting held on 14<sup>th</sup> November, 2024 submitted on 16<sup>th</sup> November, 2024, we are hereby submitting unaudited standalone and consolidated financial statements for your perusal.

We kindly request you to consider our financial results and refrain from imposing additional penalties.

We apologize for any inconvenience caused and appreciate your understanding in this matter.

Thanking you,

Yours faithfully,

**FOR DOCMODE HEALTH TECHNOLOGIES LIMITED**


**PAULSON PAUL THAZHATHEDATH**  
**WHOLETEIME DIRECTOR**  
**DIN: 02301881**

**DocMode Health Technologies Limited**  
*(Formerly known as Docmode Health Technologies Private Limited)*  
CIN : U74999MH2017PLC297413  
Balance Sheet as at September 30,2024


Indian Rupees in Lacs

| Particulars  | Note      | September 30,2024 | March 31,2024   |
|--|-----------|-------------------|-----------------|
| <b>I. EQUITY AND LIABILITIES</b>                         |           |                   |                 |
| <b>1 Shareholder's funds</b>                             |           |                   |                 |
| (a) Share capital  | <b>3</b>  | 314.28            | 314.28          |
| (b) Reserves and surplus                                 | <b>4</b>  | 672.53            | 724.19          |
| (c) Money received against share warrants                |           | -                 | -               |
| <b>2 Share application money pending allotment</b>       |           | -                 | -               |
| <b>3 Non-current liabilities</b>                         |           |                   |                 |
| (a) Long Term Borrowings                                 | <b>5</b>  | 252.24            | 438.20          |
| (b) Deferred Tax Liabilities (Net)                       |           | -                 | -               |
| (c) Other Long Term Liabilities                          |           | -                 | -               |
| (d) Long Term Provisions                                 | <b>6</b>  | 62.37             | 66.28           |
| <b>4 Current liabilities</b>                             |           |                   |                 |
| (a) Short Term Borrowings                                | <b>7</b>  | 693.03            | 479.82          |
| (b) Trade Payables                                       | <b>8</b>  | 220.33            | 281.59          |
| (c) Other Current Liabilities                            | <b>9</b>  | -                 | -               |
| (d) Short Term Provisions                                | <b>10</b> | 398.50            | 357.35          |
| <b>TOTAL</b>   |           | <b>2,613.28</b>   | <b>2,661.71</b> |
| <b>II. ASSETS</b>  |           |                   |                 |
| <b>1 Non-current assets</b>                              |           |                   |                 |
| (a) Property, Plant and Equipment and Intangible Assets  | <b>11</b> |                   |                 |
| (i) Property, Plant and Equipment                        |           | 136.14            | 95.21           |
| (ii) Intangible Assets                                   |           | 1.22              | 1.61            |
| (iii) Capital Work-In-Progress                           |           | -                 | -               |
| (iv) Intangible Assets under Development                 |           | 979.77            | 849.92          |
| (b) Non Current Investments                              | <b>12</b> | 110.10            | 110.10          |
| (c) Deferred Tax Assets (net)                            | <b>13</b> | 18.09             | 18.71           |
| (d) Long-term Loans and Advances                         | <b>14</b> | 18.58             | 7.58            |
| (e) Other Non Current Assets                             | <b>15</b> | 12.91             | 13.13           |
| <b>2 Current assets</b>                                  |           |                   |                 |
| (a) Current Investments                                  | <b>16</b> | 26.41             | 16.24           |
| (b) Inventories  | <b>17</b> | 349.20            | 251.39          |
| (c) Trade Receivables                                    | <b>18</b> | 471.08            | 790.90          |
| (d) Cash and Cash Equivalents                            | <b>19</b> | 209.99            | 308.76          |
| (e) Short Term Loans and Advances                        | <b>20</b> | 264.40            | 198.17          |
| (f) Other Current Assets                                 | <b>21</b> | 15.40             | -               |
| <b>TOTAL</b>   |           | <b>2,613.28</b>   | <b>2,661.71</b> |
| Significant Accounting Policies                          | <b>2</b>  |                   |                 |
| The notes are integral parts of the financial statements |           |                   |                 |

for DocMode Health Technologies Limited

  
**Paulson Paul Thazhathedath**  
Whole Time Director  
DIN 02301881

Place : Mumbai  
Date : November 14, 2024

  
**Hans Albert Lewis**  
Wholetime Director & CFO  
DIN: 02301853  
PAN: ACOPL6883G  
Place : Mumbai  
Date : November 14, 2024

**DocMode Health Technologies Limited**  
*(Formerly known as Docmode Health Technologies Private Limited)*  
CIN : U74999MH2017PLC297413  
**Standalone Statement of Financial Results for the Half year ended September 30, 2024**

Indian Rupees in Lacs

| Particulars   | For half year ended |                 |                   | For year ended  |                 |
|---|---------------------|-----------------|-------------------|-----------------|-----------------|
|   | September 30,2024   | March 31,2024   | September 30,2023 | March 31,2024   | March 31,2023   |
|   | Unaudited           | Unaudited       | Audited           | Audited         | Audited         |
| I. Revenue from Operations  | 2,041.81            | 1,640.31        | 2,360.42          | 4,000.73        | 3,287.84        |
| II. Other Income  | 84.10               | 7.31            | 6.28              | 13.59           | 9.57            |
| <b>III. Total Income (I + II)</b>   | <b>2,125.91</b>     | <b>1,647.62</b> | <b>2,366.70</b>   | <b>4,014.33</b> | <b>3,297.42</b> |
| IV. <b>Expenses:</b>  |                     |                 |                   |                 |                 |
| Cost of Materials Consumed  | -                   | -               | -                 | -               | -               |
| Cost of Services  | 135.88              | 80.89           | 206.07            | 286.96          | 94.47           |
| Changes in inventories:   | (97.82)             | 1.19            | 0.39              | 1.58            | (2.55)          |
| Employee benefits Expense   | 178.80              | 202.84          | 292.37            | 495.21          | 555.62          |
| Finance Costs   | 108.79              | 81.44           | 83.78             | 165.22          | 112.88          |
| Depreciation and Amortization Expense   | 14.14               | 0.91            | 1.53              | 2.44            | 2.13            |
| Other Expenses  | 1,837.16            | 1,438.18        | 1,590.16          | 3,028.34        | 2,265.72        |
| Total expenses  | 2,176.96            | 1,805.44        | 2,174.31          | 3,979.75        | 3,028.27        |
| <b>V Profit before exceptional and extraordinary items and tax (III- IV)</b>  | <b>(51.05)</b>      | <b>(157.82)</b> | <b>192.39</b>     | <b>34.58</b>    | <b>269.15</b>   |
| VI Exceptional Items  | -                   | -               | -                 | -               | -               |
| <b>VII Profit before extraordinary items and tax (V - VI)</b>                 | <b>(51.05)</b>      | <b>(157.82)</b> | <b>192.39</b>     | <b>34.58</b>    | <b>269.15</b>   |
| VIII Extraordinary items  | -                   | -               | -                 | -               | -               |
| <b>IX Profit before tax (VII- VIII)</b>                                       | <b>(51.05)</b>      | <b>(157.82)</b> | <b>192.39</b>     | <b>34.58</b>    | <b>269.15</b>   |
| X <b>Tax expense:</b>   |                     |                 |                   |                 |                 |
| (1) Current tax   | -                   | (38.00)         | 58.00             | 20.00           | 82.50           |
| Less : MAT Credit Entitlement   | -                   | -               | -                 | -               | -               |
| (2) Deferred tax Liability/(Asset)  | 0.62                | (3.43)          | (0.85)            | (4.28)          | (7.49)          |
| (3) Tax in respect of earlier years   | -                   | 0.26            | (0.77)            | (0.51)          | (0.73)          |
| (4) Profit / (Loss) of Prior Period Depreciation                              | -                   | -               | -                 | -               | -               |
|   | 0.62                | (41.17)         | 56.38             | 15.21           | 74.28           |
| <b>XI Profit (Loss) for the period from continuing operations (IX-X)</b>      | <b>(51.66)</b>      | <b>(116.64)</b> | <b>136.01</b>     | <b>19.37</b>    | <b>194.87</b>   |
| XII Profit/(loss) from discontinuing operations                               | -                   | -               | -                 | -               | -               |
| XIII Tax expense of discontinuing operations                                  | -                   | -               | -                 | -               | -               |
| <b>XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)</b> | <b>-</b>            | <b>-</b>        | <b>-</b>          | <b>-</b>        | <b>-</b>        |
| <b>XV Profit (Loss) for the period (XI + XIV)</b>                             | <b>(51.66)</b>      | <b>(116.64)</b> | <b>136.01</b>     | <b>19.37</b>    | <b>194.87</b>   |
| XVI <b>Earnings per equity share of Rs. 10 each</b>                           |                     |                 |                   |                 |                 |
| Basic   | (1.64)              | (3.71)          | 5.93              | 0.62            | 8.50            |
| Diluted   | (1.64)              | (3.71)          | 5.93              | 0.62            | 8.50            |
| <b>Significant Accounting Policies</b>  |                     |                 |                   |                 |                 |
| The notes are integral parts of the financial statements                      |                     |                 |                   |                 |                 |


- The Above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the listing Regulations") have been approved by the Board of Directors at their respective meeting held on November 14, 2024. The Statutory Auditors of the company have carried out the audit of the aforesaid results for the half year and year ended 30th September, 2024. The Financial Results have been prepared in accordance with the Accounting Standards as prescribed under section 133 of the Companies Act, 2013 read with rules 7 of Companies (Account) Rules 2014 by the Ministry of Corporate Affairs and Amendments thereof.
- As per Ministry of Corporate Affairs Notification dated February 16, 2015, Companies Whose Securities are listed on SME Exchange as referred in Chapter XB of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of Ind AS.
- The above Standalone Financial Results have been reviewed by the Audit Committee and Approved by the Board of Directors at their respective meeting held on November 14, 2024 and have been audited by the Statutory Auditors of the Company.
- The Primary reporting of the company has been performed on the basis of business segment. The management of the company has evaluated the company's overall performance as one segment which is "Transforming Learning and Practice" and operates in a single business segment based on the nature of business, the risk and returns, the organisation structure and the internal control Financial systems. Accordingly, the figures appearing in these financial statements relate to the company's single business segment. The company has significant operations based in India, hence there are no reportable geographical segments in Standalone Financial Statements.
- The Figures for half year ended on 31st March 2024 are the balancing figures between the audited figures in respect of the financial year and the reviewed year to date figures for the half year ended on 30th September 2024.
- Previous period figures have been regrouped/reclassified and restated wherever considered necessary to make them comparable.
- The balance appearing under the trade payables, Loans & Advances, Other Current Liabilities are subject to confirmation and reconciliation and consequent adjustments, if any, will be accounted for in the year of confirmation and / or reconciliation.
- The company has issued and allotted 8,49,600 equity shares of Rs. 10 Each at premium of Rs.69 Per Equity Share through Initial Public Offer Aggregating to Rs. 671.18 Lakhs. The details of utilization of the net IPO proceeds is mentioned below:

| Particulars  | As per Prospectus | Funds Utilised |
|--|-------------------|----------------|
| Purchase of IT infrastructure and operating system | 303.08            | 258.08         |
| Meeting incremental working capital requirements   | 200.00            | 200.00         |
| General corporate purposes                         | 103.10            | 103.10         |

for DocMode Health Technologies Limited

  
**Paulson Paul Thazhathelath**  
Whole Time Director  
DIN 02301881

Place : Mumbai  
November 14, 2024


  
**Hans Albert Lewis**  
Whole Time Director & CFO  
DIN: 02301853  
PAN: ACOPL6883G  
Place : Mumbai  
November 14, 2024


**DocMode Health Technologies Limited**  
**(Formerly known as Docmode Health Technologies Private Limited)**  
CIN : U74999MH2017PLC297413  
**Statement of Cash Flows for the period ended September 30, 2024**

Indian Rupees in Lacs

| (A) CASH FLOW FROM OPERATING ACTIVITIES                  | September<br>30,2024 | March 31,2024   |
|--|----------------------|-----------------|
| Net Profit before Tax and Extraordinary Items            | (51.05)              | 34.58           |
| <b>Adjusted for</b>                                      |                      |                 |
| Depreciation   | 14.14                | 2.44            |
| Profit on Sale of Fixed Assets                           | -                    | -               |
| Provision for Gratuity                                   | (3.91)               | 17.43           |
| Interest Expenses  | 108.79               | 165.22          |
| <b>Operating Profit before Working Capital changes</b>   | <b>67.98</b>         | <b>219.66</b>   |
| Adjutments for changes in working capital                |                      |                 |
| (Increase)/Decrease in Inventories                       | (97.82)              | 1.58            |
| (Increase)/Decrease in Trade and Other Receivables       | 319.82               | 38.56           |
| (Increase)/Decrease in Short Loans & Advances            | (66.23)              | 13.44           |
| (Increase)/Decrease in Long term Loans & Advances        | (11.00)              | (7.46)          |
| (Increase)/Decrease in Other Current Assets              | (15.40)              | -               |
| Increase/(Decrease) in Trade Payables                    | (61.26)              | (19.36)         |
| Increase/(Decrease) in Other Non Current liabilities     | -                    | -               |
| Increase/(Decrease) in Current liabilities               | -                    | (0.41)          |
| Increase/(Decrease) in Short Term Provisions             | 41.15                | 202.32          |
| <b>Cash generated from operations</b>                    | <b>177.25</b>        | <b>448.34</b>   |
| Direct Taxes Paid  | -                    | 0.51            |
| <b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>           | <b>177.25</b>        | <b>448.85</b>   |
| <b>(B) CASH FLOW FROM INVESTING ACTIVITIES</b>           |                      |                 |
| Sale/ (Purchase) of Fixed Assets                         | (184.53)             | (741.73)        |
| Sale/ (Purchase) of Investments                          | (10.17)              | (6.41)          |
| Rent Deposit paid to landlord for office premises        | 0.22                 | (6.67)          |
| <b>NET CASH USED IN INVESING ACTIVITIES</b>              | <b>(194.48)</b>      | <b>(754.81)</b> |
| <b>(C) CASH FLOW FROM FINANCING ACTIVITIES</b>           |                      |                 |
| Proceeds/(Repayment) from long term borrowings           | (185.96)             | (3.29)          |
| Proceeds from Short Term Borrowings                      | 213.20               | 73.37           |
| Proceeds from issue of Shares                            | -                    | 671.18          |
| Interest paid  | (108.79)             | (165.22)        |
| <b>NET CASH FROM FINANCING ACTIVITIES</b>                | <b>(81.55)</b>       | <b>576.04</b>   |
| <b>NET INCREASE IN CASH AND CASH EQUIVALANTS (A+B+C)</b> | <b>(98.78)</b>       | <b>270.09</b>   |
| <b>OPENING BALANCE OF CASH AND CASH EQUIVALANTS</b>      | <b>308.76</b>        | <b>38.68</b>    |
| <b>CLOSING BALANCE OF CASH AND CASH EQUIVALANTS</b>      | <b>209.99</b>        | <b>308.76</b>   |

for DocMode Health Technologies Limited


  
**Paulson Paul Thazhathedath**  
Whole Time Director  
DIN 02301881


  
**Hans Albert Lewis**  
Wholetime Director & CFO  
DIN: 02301853  
PAN: ACOPL6883G

**DocMode Health Technologies Limited**  
*(Formerly known as Docmode Health Technologies Private Limited)*  
CIN : U74999MH2017PLC297413  
**Consolidated Balance Sheet as at September 30,2024**

| Particulars  | Note | September 30,2024 | March 31,2024   |
|--|------|-------------------|-----------------|
| <b>I. EQUITY AND LIABILITIES</b>                         |      |                   |                 |
| <b>1 Shareholder's funds</b>                             |      |                   |                 |
| (a) Share capital  | 3    | 314.28            | 314.28          |
| (b) Reserves and surplus                                 | 4    | 671.09            | 723.20          |
| (c) Money received against share warrants                |      | -                 | -               |
| <b>Minority Interest</b>                                 | 5    | (0.02)            | -               |
| <b>2 Share application money pending allotment</b>       |      | -                 | -               |
| <b>3 Non-current liabilities</b>                         |      |                   |                 |
| (a) Long Term Borrowings                                 | 6    | 252.24            | 438.20          |
| (b) Deferred Tax Liabilities (Net)                       |      | -                 | -               |
| (c) Other Long Term Liabilities                          |      | -                 | -               |
| (d) Long Term Provisions                                 | 7    | 62.37             | 66.28           |
| <b>4 Current liabilities</b>                             |      |                   |                 |
| (a) Short Term Borrowings                                | 8    | 693.03            | 479.82          |
| (b) Trade Payables                                       | 9    | 218.88            | 279.30          |
| (c) Other Current Liabilities                            | 10   | -                 | -               |
| (d) Short Term Provisions                                | 11   | 398.50            | 338.48          |
| <b>TOTAL</b>   |      | <b>2,610.37</b>   | <b>2,639.56</b> |
| <b>II. ASSETS</b>  |      |                   |                 |
| <b>1 Non-current assets</b>                              |      |                   |                 |
| (a) Property, Plant and Equipment and Intangible Assets  | 12   |                   |                 |
| (i) Property, Plant and Equipment                        |      | 136.14            | 95.21           |
| (ii) Intangible Assets                                   |      | 1.22              | 1.61            |
| (iii) Capital Work-In-Progress                           |      | -                 | -               |
| (iv) Intangible Assets under Development                 |      | 979.77            | 849.92          |
| (b) Non Current Investments                              | 13   | 110.00            | 110.00          |
| (c) Deferred Tax Assets (net)                            | 14   | 18.10             | 18.71           |
| (d) Long-term Loans and Advances                         | 15   | 2.68              | 0.03            |
| (e) Other Non Current Assets                             | 16   | 12.91             | 13.13           |
| <b>2 Current assets</b>                                  |      |                   |                 |
| (a) Current Investments                                  | 17   | 26.41             | 16.24           |
| (b) Inventories  | 18   | 360.36            | 251.39          |
| (c) Trade Receivables                                    | 19   | 471.08            | 790.90          |
| (d) Cash and Cash Equivalents                            | 20   | 211.72            | 310.28          |
| (e) Short Term Loans and Advances                        | 21   | 264.59            | 182.15          |
| (f) Other Current Assets                                 | 22   | 15.40             | -               |
| <b>TOTAL</b>   |      | <b>2,610.37</b>   | <b>2,639.56</b> |
| Significant Accounting Policies                          | 2    |                   |                 |
| The notes are integral parts of the financial statements |      |                   |                 |

**for DocMode Health Technologies Limited**

  
**Paulson Paul Thazhathedath**  
Whole Time Director  
DIN 02301881

  
**Hans Albert Lewis**  
Whole Time Director & CFO  
DIN 02301853  
PAN: ACOPL6883G  
Place : Mumbai  
Date : November 14, 2024

Place : Mumbai  
Date : November 14, 2024

**DocMode Health Technologies Limited**  
*(Formerly known as Docmode Health Technologies Private Limited)*  
CIN : U74999MH2017PLC297413  
**Consolidated Statement of Financial Results for the Half year ended September 30, 2024**

Indian Rupees in Lacs

| Particulars   | For half year ended |                 |                   | For year ended  |                 |
|---|---------------------|-----------------|-------------------|-----------------|-----------------|
|   | September 30,2024   | March 31, 2024  | September 30,2023 | March 31,2024   | March 31,2023   |
|   | Unaudited           | Unaudited       | Audited           | Audited         | Audited         |
| I. Revenue from Operations  | 2,041.81            | 1,640.31        | 2,360.42          | 4,000.73        | 3,287.84        |
| II. Other Income  | 84.10               | 7.31            | 6.28              | 13.59           | 9.57            |
| <b>III. Total Income (I + II)</b>   | <b>2,125.91</b>     | <b>1,647.62</b> | <b>2,366.70</b>   | <b>4,014.33</b> | <b>3,297.42</b> |
| IV. Expenses:   |                     |                 |                   |                 |                 |
| Cost of Materials Consumed  |                     |                 |                   | -               | -               |
| Cost of Services  | 135.88              | 81.65           | 206.07            | 287.73          | 94.47           |
| Changes in inventories  | (108.97)            | 1.19            | 0.39              | 1.58            | (2.55)          |
| Employee benefits Expense   | 178.80              | 202.74          | 292.37            | 495.11          | 555.62          |
| Finance Costs   | 109.26              | 81.94           | 83.78             | 165.72          | 112.89          |
| Depreciation and Amortization Expense   | 14.14               | 0.91            | 1.53              | 2.44            | 2.13            |
| Other Expenses  | 1,848.31            | 1,437.62        | 1,590.16          | 3,027.78        | 2,265.77        |
| Total expenses  | 2,177.43            | 1,806.05        | 2,174.31          | 3,980.36        | 3,028.33        |
| <b>V Profit before exceptional and extraordinary items and tax (III- IV)</b>  | <b>(51.52)</b>      | <b>(158.42)</b> | <b>192.39</b>     | <b>33.97</b>    | <b>269.09</b>   |
| VI Exceptional Items  |                     |                 |                   |                 |                 |
| VII <b>Profit before extraordinary items and tax (V - VI)</b>                 | <b>(51.52)</b>      | <b>(158.42)</b> | <b>192.39</b>     | <b>33.97</b>    | <b>269.09</b>   |
| VIII Extraordinary items  |                     |                 |                   |                 |                 |
| IX <b>Profit before tax (VII- VIII)</b>                                       | <b>(51.52)</b>      | <b>(158.42)</b> | <b>192.39</b>     | <b>33.97</b>    | <b>269.09</b>   |
| X Tax expense:  |                     |                 |                   |                 |                 |
| (1) Current tax   | -                   | (38.00)         | 58.00             | 20.00           | 82.50           |
| Less : MAT Credit Entitlement   |                     |                 |                   |                 |                 |
| (2) Deferred tax Liability/(Asset)  | 0.62                | (3.43)          | (0.85)            | (4.28)          | (7.50)          |
| (3) Tax in respect of earlier years   | -                   | 0.26            | (0.77)            | (0.51)          | (0.73)          |
| (4) Profit / (Loss) of Prior Period Depreciation                              |                     |                 |                   |                 |                 |
|   | 0.62                | (41.17)         | 56.38             | 15.21           | 74.27           |
| <b>XI Profit (Loss) for the period from continuing operations (IX-X)</b>      | <b>(52.13)</b>      | <b>(117.25)</b> | <b>136.01</b>     | <b>18.76</b>    | <b>194.82</b>   |
| XII Profit/(loss) from discontinuing operations                               |                     |                 |                   |                 |                 |
| XIII Tax expense of discontinuing operations                                  |                     |                 |                   |                 |                 |
| XIV <b>Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)</b> |                     |                 |                   |                 |                 |
| <b>XV Profit (Loss) for the period (XI + XIV)</b>                             | <b>(52.13)</b>      | <b>(117.25)</b> | <b>136.01</b>     | <b>18.76</b>    | <b>194.82</b>   |
| XVI <b>Earnings per equity share of Rs. 10 each</b>                           |                     |                 |                   |                 |                 |
| Basic   | (1.66)              | (3.73)          | 5.93              | 0.60            | 8.50            |
| Diluted   | (1.66)              | (3.73)          | 5.93              | 0.60            | 8.50            |
| Significant Accounting Policies   |                     |                 |                   |                 |                 |
| The notes are integral parts of the financial statements                      |                     |                 |                   |                 |                 |


- The Above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the listing Regulations") have been approved by the Board of Directors at their respective meeting held on November 14, 2024. The Statutory Auditors of the company have carried out the audit of the aforesaid results for the half year and year ended 30th September, 2024. The Financial Results have been prepared in accordance with the Accounting Standards as prescribed under section 133 of the Companies Act, 2013 read with rules 7 of Companies (Account) Rules 2014 by the Ministry of Corporate Affairs and Amendments thereof.
- As per Ministry of Corporate Affairs Notification dated February 16, 2015, Companies Whose Securities are listed on SME Exchange as referred in Chapter XB of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of Ind AS.
- The above Standalone Financial Results have been reviewed by the Audit Committee and Approved by the Board of Directors at their respective meeting held on November 14, 2024 and have been audited by the Statutory Auditors of the Company.
- The Primary reporting of the company has been performed on the basis of business segment. The management of the company has evaluated the company's overall performance as one segment which is "Transforming Learning and Practice" and operates in a single business segment based on the nature of business, the risk and returns, the organisation structure and the internal control Financial systems. Accordingly, the figures appearing in these financial statements relate to the company's single business segment. The company has significant operations based in India, hence there are no reportable geographical segments in Standalone Financial Statements.
- The Figures for half year ended on 31st March 2024 are the balancing figures between the audited figures in respect of the financial year and the reviewed year to date figures for the half year ended on 30th September 2024.
- Previous period figures have been regrouped/reclassified and restated wherever considered necessary to make them comparable.
- The balance appearing under the trade payables, Loans & Advances, Other Current Liabilities are subject to confirmation and reconciliation and consequent adjustments, if any, will be accounted for in the year of confirmation and / or reconciliation.
- The company has issued and allotted 8,49,600 equity shares of Rs. 10 Each at premium of Rs.69 Per Equity Share through Initial Public Offer Aggregating to Rs. 671.18 Lakhs. The details of utilization of the net IPO proceeds is mentioned below:

| Particulars  | As per Prospectus | Funds Utilised |
|--|-------------------|----------------|
| Purchase of IT infrastructure and operating system | 303.08            | 258.08         |
| Meeting incremental working capital requirements   | 200.00            | 200.00         |
| General corporate purposes                         | 103.10            | 103.10         |

for DocMode Health Technologies Limited

  
**Paulson Paul Thazhathedath**  
Whole Time Director  
DIN 02301881

Place : Mumbai  
November 14, 2024

  
**Hans Albert Lewis**  
Whole Time Director & CFO  
DIN 02301853  
PAN: ACOPL6883G  
Place : Mumbai  
November 14, 2024


**DocMode Health Technologies Limited**  
**(Formerly known as Docmode Health Technologies Private Limited)**  
**CIN : U74999MH2017PLC297413**  
**Statement of Cash Flows for the period ended September 30, 2024**

Indian Rupees in Lacs

| (A) CASH FLOW FROM OPERATING ACTIVITIES                  | September<br>30,2024 | March 31,2024 |
|--|----------------------|---------------|
| Net Profit before Tax and Extraordinary Items            | (51.05)              | 34.58         |
| <b>Adjusted for</b>                                      |                      |               |
| Depreciation   | 14.14                | 2.44          |
| Profit on Sale of Fixed Assets                           | -                    | -             |
| Provision for Gratuity                                   | (3.91)               | 17.43         |
| Interest Expenses  | 108.79               | 165.22        |
| <b>Operating Profit before Working Capital changes</b>   | 67.98                | 219.66        |
| Adjustments for changes in working capital               |                      |               |
| (Increase)/Decrease in Inventories                       | (97.82)              | 1.58          |
| (Increase)/Decrease in Trade and Other Receivables       | 319.82               | 38.56         |
| (Increase)/Decrease in Short Loans & Advances            | (66.23)              | 13.44         |
| (Increase)/Decrease in Long term Loans & Advances        | (11.00)              | (7.46)        |
| (Increase)/Decrease in Other Current Assets              | (15.40)              | -             |
| Increase/(Decrease) in Trade Payables                    | (61.26)              | (19.36)       |
| Increase/(Decrease) in Other Non Current liabilities     | -                    | -             |
| Increase/(Decrease) in Current liabilities               | -                    | (0.41)        |
| Increase/(Decrease) in Short Term Provisions             | 41.15                | 202.32        |
| <b>Cash generated from operations</b>                    | 177.25               | 448.34        |
| Direct Taxes Paid  | -                    | 0.51          |
| <b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>           | 177.25               | 448.85        |
| <b>(B) CASH FLOW FROM INVESTING ACTIVITIES</b>           |                      |               |
| Sale/ (Purchase) of Fixed Assets                         | (184.53)             | (741.73)      |
| Sale/ (Purchase) of Investments                          | (10.17)              | (6.41)        |
| Rent Deposit paid to landlord for office premises        | 0.22                 | (6.67)        |
| <b>NET CASH USED IN INVESTING ACTIVITIES</b>             | (194.48)             | (754.81)      |
| <b>(C) CASH FLOW FROM FINANCING ACTIVITIES</b>           |                      |               |
| Proceeds/(Repayment) from long term borrowings           | (185.96)             | (3.29)        |
| Proceeds from Short Term Borrowings                      | 213.20               | 73.37         |
| Proceeds from issue of Shares                            | -                    | 671.18        |
| Interest paid  | (108.79)             | (165.22)      |
| <b>NET CASH FROM FINANCING ACTIVITIES</b>                | (81.55)              | 576.04        |
| <b>NET INCREASE IN CASH AND CASH EQUIVALANTS (A+B+C)</b> | (98.78)              | 270.09        |
| <b>OPENING BALANCE OF CASH AND CASH EQUIVALANTS</b>      | 308.76               | 38.68         |
| <b>CLOSING BALANCE OF CASH AND CASH EQUIVALANTS</b>      | 209.99               | 308.76        |

for DocMode Health Technologies Limited

  
**Paulson Paul Thazhathadath**  
 Whole Time Director  
 DIN 02301881

  
**Hans Albert Lewis**  
 Wholetime Director & CFO  
 DIN: 02301853  
 PAN: ACOPL6883G